B
BioAtla D
D
BCAB
2.20000
USD
0.14
(6.54%)
Market Closed
Volume
86,937
EPS
0
Div Yield
0
P/E
-1
Market Cap
106,338,621
Novo Nordisk Surges in Profit and Sales
6 months ago
Stocks news More
Title: BioAtla
Sector: Healthcare
Industry: Biotechnology
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.